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Patients with breast cancer and bone metastases often experience skeletal complications (skeletal-related events
[SREs]: pathologic fracture, radiation to bone, surgery to bone or spinal cord compression). Prospective data on the
health resource burden of SREs are needed for planning healthcare requirements and estimating the value of new
treatments, but limited data are available. This prospective, observational study collected health resource utilization
(HRU) data independently attributed to SREs by investigators. Eligible patients had bone metastases secondary to
breast cancer, life expectancy ≥6 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and
at least one SRE in the 97 days before enrollment. Data, collected retrospectively for 97 days before enrollment and
prospectively for 18–21 months, included number and duration of inpatient stays, outpatient visits, emergency
room visits and procedures. Altogether, 223 patients were enrolled from Germany, Italy, Spain and the UK. Of the
457 SREs, 118 (25.8%) were associated with inpatient stays. The mean duration of stay was 19.5 (standard deviation
[SD] 19.2) days per SRE (based on 117 SREs). Surgery to bone and spinal cord compression were the SREs most
likely to require inpatient stays (77.8% and 57.9% of SREs, respectively), while radiation to bone was the least likely
(9.7%). Spinal cord compression required the longest inpatient stay per event (34.2 [SD 30.2] days) and radiation to
bone the shortest (14.3 [SD 10.2] days). Overall, 342 SREs (74.8%) required an outpatient visit, with radiation to bone
the most likely (85.7%), and surgery to bone the least likely (42.6%). Radiation to bone was also associated with the
greatest number of outpatient visits per event (6.8 [SD 6.7] visits). All SREs were associated with substantial HRU
therefore, preventing SREs in patients with breast cancer may reduce the burden imposed on healthcare systems.
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Breast cancer is the most common cancer in women,
with nearly half a million new cases diagnosed in Europe
in 2008 (Steliarova-Foucher et al. 2012). Up to 75% of
patients with advanced breast cancer develop bone me-
tastases (Coleman 1997), which are often associated with
skeletal or bone complications, otherwise referred to as
skeletal-related events (SREs) and commonly comprising
pathologic fracture, radiation to bone, surgery to bone,
and spinal cord compression (Coleman 2001). The high* Correspondence: diana.lueftner@charite.de
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in any medium, provided the original work is pfrequency of bone metastases and associated complica-
tions in patients with breast cancer means SREs contrib-
ute significantly to the clinical and economic burden of
the disease.
SREs can be debilitating and patients frequently experi-
ence a reduction in quality of life, with significant de-
creases in physical and functional well-being (Weinfurt
et al. 2004). SREs are associated with considerable morbid-
ity, the worst being spinal cord compression, which can
lead to paralysis, and pathologic fractures, which may
result in disability or the need for surgery, with the poten-
tial for additional perioperative morbidity (Coleman 2006;
Katzer et al. 2002). As might be expected, SREs oftenan open access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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mobility and reduces quality of life (Katzer et al. 2002;
DePuy et al. 2007; Costa et al. 2008). SREs are also associ-
ated with an increased risk of death (Norgaard et al. 2010;
Saad et al. 2007).
In addition to the patient impact, SREs impose a sub-
stantial burden on healthcare resources. Planning future
resource requirements and estimating the value of new
treatment options requires data on the resource burden
of SREs. However, there is a lack of prospective data on
the impact of SREs on health resource utilization (HRU).
Several retrospective US studies have suggested that
SREs increase HRU (Delea et al. 2004, 2006; Lage et al.
2008; Schulman and Kohles 2007), and studies in Spain,
France, and Portugal have demonstrated that SREs in-
crease HRU and costs (Pockett et al. 2010; Decroisette
et al. 2011; Felix et al. 2011; Svendsen et al. 2013). How-
ever, these studies were restricted to individual countries
and to our knowledge there have been no large, inter-
national, prospective studies investigating the differential
contribution of the various types of SREs to HRU.
We therefore designed a prospective, observational,
multinational study to evaluate the HRU associated with
each type of SRE in patients with bone metastases or le-
sions secondary to breast, prostate or lung cancer, or
multiple myeloma in Canada, Germany, Italy, Spain, the
United Kingdom (UK) and the United States of America
(USA). Here, we report the data for patients with ad-
vanced breast cancer from the four European countries
(Germany, Italy, Spain, and the UK).
Methods
Patients
Patients aged 18 years or older with bone metastases
secondary to breast cancer and a life expectancy of at
least 6 months were eligible for inclusion in the study.
In addition, patients were required to have an Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus of 0, 1 or 2, and to have experienced at least one
SRE in the 97 days before signing informed consent or
up to 7 days afterward. Patients who were enrolled in an
investigational drug trial for treatment of bone metasta-
ses or prevention of SREs were excluded from the study.
Study design
Patient demographics and information on disease history
were collected at enrollment. HRU data for each patient
were collected retrospectively by chart review for all
SREs occurring in the 97-day period before enrollment,
and prospectively for the duration of their involvement
in the study. The planned follow-up period for patients in
the study was up to 18–21 months. SREs were defined
as pathologic fracture (either vertebral or non-vertebral),
radiation to bone, surgery to bone, or spinal cord com-pression; investigators independently attributed HRU to
SREs. HRU outcome measures included: the number, dur-
ation and facility type of inpatient stays; the number and
facility type of outpatient visits; the number of emergency
room visits; the number, duration and facility type of nurs-
ing home/long-term care facility stays; the number of
home health visits; and the type of procedure.
Statistical analyses
As described previously (Hechmati et al. 2011), all ana-
lyses were descriptive. HRU was summarized by SRE
type, and the mean HRU per SRE type was calculated by
dividing the total HRU attributed to SREs by the total
number of SREs of the same type. The mean duration of
inpatient stay per SRE was calculated as the total num-
ber of inpatient days divided by the total number of
SREs that were associated with an inpatient stay (if an
SRE resulted in multiple inpatient stays, the total dur-
ation of all inpatient stays was used). Data on inpatient
stays by facility type reported SREs with at least one in-
patient stay within the facility type and SRE type. When
an SRE required stays in more than one facility type, a
stay was attributed to each facility type.
If an SRE required multiple inpatient stays within one
facility type, the total duration of inpatient stays was
counted. If radiation or surgery to bone was carried out
as a result of another SRE (i.e. treatment of a primary
SRE, such as pathologic fracture), the investigator had
the option of attributing HRU to the primary SRE.
Therefore, SREs determined to be secondary to a pri-
mary SRE were excluded from the analysis.
The data are primarily reported as mean values, rather
than medians, because this better describes the total re-
sources used at a population level: information that is
required for healthcare policy decisions (Thompson and
Barber 2000). Median values are also reported in the fig-
ures to illustrate the distribution of data when sample




At the time of the final analysis, 223 patients with a pri-
mary diagnosis of breast cancer who met the eligibility
criteria were enrolled across the European sites. The
mean (standard deviation [SD]) length of follow-up for
these patients ranged from 7.1 (5.2) to 10.3 (5.4) months
(Table 1).
Baseline characteristics and disease history were gener-
ally similar across the four countries (Table 1). There
was a higher proportion of patients with an ECOG per-
formance status of 2 in Spain (41.9%) than in the other
countries (20.0–22.2%), and a correspondingly lower
proportion of patients with ECOG performance status of
Table 1 Baseline demographics and disease history
Characteristic Germany (n = 85) Italy (n = 62) Spain (n = 31) UK (n = 45)
Follow-up time, months, mean (SD) 10.3 (5.4) 8.6 (4.8) 7.1 (5.2) 7.4 (5.5)
Female, n (%) 84 (98.8) 61 (98.4) 28 (90.3) 45 (100.0)
Ethnic group, n (%)
White or Caucasian 85 (100.0) 61 (98.4) 30 (96.8) 44 (97.8)
Othera 0 (0.0) 1 (1.6) 1 (3.2) 1 (2.2)
Age, years, median (range) 62.0 (40, 81) 60.0 (36, 83) 56.0 (38, 79) 58.0 (32, 92)
≥ 65 years, n (%) 34 (40.0) 21 (33.9) 11 (35.5) 17 (37.8)
ECOG performance status, n (%)
0 27 (31.8) 18 (29.0) 6 (19.4) 14 (31.1)
1 41 (48.2) 31 (50.0) 12 (38.7) 21 (46.7)
2 17 (20.0) 13 (21.0) 13 (41.9) 10 (22.2)
History of SREsb n (%) 53 (62.4) 34 (54.8) 20 (64.5) 21 (46.7)
Time since primary cancer diagnosis, months, median (Q1, Q3) 70.8 (22.9, 132.2) 39.0 (8.7, 99.1) 62.7 (27.5, 138.4) 72.2 (33.3, 118.0)
Time since bone metastasis diagnosis, months, median (Q1, Q3) 4.4 (1.8, 22.9) 4.1 (1.8, 13.3) 4.9 (1.8, 39.6) 9.6 (3.0, 32.2)
a‘Other’ includes Asian and Hispanic or Latino ethnic groups; bbefore the 90-day period preceding the signing of informed consent.
ECOG-Eastern Cooperative Oncology Group, Q-quartile, SD-standard deviation, SRE-skeletal-related event, UK-United Kingdom.
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The median time from diagnosis of the primary cancer to en-
rollment was notably shorter for patients in Italy (39.0 months)
than for the other countries (62.7–72.2 months), while the
median time from bone metastases detection to enroll-
ment was notably longer in the UK (9.6 months) than
elsewhere (4.1–4.9 months).
Skeletal-related events
Eligible patients experienced a total of 489 SREs. Ana-
lysis of the crude SRE data (including SREs excluded
from the HRU analysis) showed that the SRE rate per
patient-year was consistent across Germany, Italy, and
Spain (2.0 SREs per patient-year), but was higher in the





















Figure 1 Number of SREs included in the HRU analysis by country an
PF pathologic fracture, RB radiation to bone, SB surgery to bone, SCC spinal coSREs determined by investigators to be secondary to a
previous SRE (32 SREs), 457 SREs remained eligible for
inclusion in the HRU analysis (Figure 1). Radiation to
bone was the most common SRE, accounting for 279 of
the 457 events, while spinal cord compression was the
least common (19 events); this pattern was consistent
across all countries studied.
Health resource utilization
Inpatient stays
Overall, 118 of 457 SREs (25.8%) required hospitalization.
Although all types of SRE contributed to inpatient stays,
the proportion of SREs requiring an inpatient stay varied
greatly across SRE types (Figure 2). Spinal cord compres-
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Figure 2 Proportion of SREs requiring an inpatient stay. VF and NVF are subsets of PF n = number of SREs. NVF non-vertebral fracture,
PF pathologic fracture, RB radiation to bone, SB surgery to bone, SCC spinal cord compression, SRE skeletal-related event, VF vertebral fracture.
Lüftner et al. SpringerPlus 2014, 3:328 Page 4 of 10
http://www.springerplus.com/content/3/1/328inpatient stays (with 57.9% and 77.8% requiring stays, re-
spectively), while radiation to bone was the least likely
(9.7%). The rates of inpatient stays were generally consist-
ent across all countries, with the exception of vertebral
fracture; for this SRE, patients in the UK were less likely to
be hospitalized (14.3%) than those from other countries
(41.7–50.0%), although the overall number of vertebral
fractures was low (n = 27).
Data on the duration of inpatient stays were collected
for 117 of the 118 SREs that required hospitalization
(data for one surgery to bone event were not collected).
All types of SREs were associated with inpatient stays of
substantial duration (Figure 3a). The mean (SD) length
of inpatient stay per SRE that required an inpatient stay
was 19.5 (19.2) days. Spinal cord compression required
the longest stay per event (34.2 [SD 30.2] days) and radi-
ation to bone the shortest (14.3 [SD 10.2] days). Across
the four countries, the overall mean length of stay
ranged from 12.9 to 27.2 days, with the UK having the
shortest mean duration and Spain the longest (Figure 3b).
In Spain, the mean length of stay for pathologic fracture
was over twice as long as that for any of the other coun-
tries (46.4 [SD 28.5] days vs. 17.2–19.8 days). However,
this probably reflects the small number of patients with
pathologic fractures requiring inpatient stays who were
recruited in Spain (n = 5) and the long duration of stay
needed for one of the recorded events (87 days). In the
UK, the mean length of stay for radiation to bone (6.5
[SD 6.2] days; six events) was less than half that of the
overall mean for radiation to bone across all four coun-
tries. Data on facility type indicated that the mean lengthof stay in oncology units/wards (the only contributor to
inpatient stays for radiation to bone in the UK) was only
6.5 (SD 6.2) days for the UK, whereas the overall mean
for all countries for oncology unit/ward stays for radi-
ation to bone was 11.0 (SD 8.3) days (Table 2).
Across all SREs, the most common facility types for in-
patient stays were surgical units/wards and oncology units/
wards, with general units/wards, rehabilitation units/wards,
radiation units/wards and ‘other’ units/wards also used fre-
quently (Table 2). Spinal cord compression and radiation
to bone were both most likely to be treated in an oncology
unit/ward. Patients with pathologic fracture were most
likely to stay in a surgical unit/ward, with a mean length of
stay of 20.2 (SD 9.2) days. Patients requiring surgery to
bone were also most likely to be treated in a surgical unit/
ward, but the mean length of stay (12.2 [SD 8.3] days) was
lower than average for this type of facility.
Outpatient visits
Outpatient visits were also common across all SREs
(Figure 4). Overall, radiation to bone required the highest
proportion of visits, with 85.7% of events requiring a visit,
and surgery to bone the lowest (42.6%). In Spain, however,
pathologic fracture was the SRE most likely to require an
outpatient visit (76.9%), with a lower proportion of radi-
ation to bone events (72.4%) requiring a visit. The propor-
tion of outpatient visits for surgery to bone showed the
most variation across countries, with a visit most likely in
the UK (61.5%) and least likely in Spain (25.0%).
The mean number of outpatient visits per SRE across all



















































































Median, days 17.0 17.0 16.5 8.0
(Q1, Q3) (10.0, 24.0) (7.0, 27.0) (10.5, 38.5) (5.0, 17.0) 
n
n
Figure 3 Mean duration of inpatient stay per SRE that required an inpatient stay. (a) by SRE type, and (b) by country. Data are shown as
mean (+standard deviation). Median (Q1, Q3) data are displayed below the graph. Data include only SREs requiring an inpatient stay. If an SRE
resulted in multiple inpatient stays, the total duration of all the inpatient stays was used. VF and NVF are subsets of PF. n = number of SREs
requiring an inpatient stay with at least one inpatient stay by SRE type. NVF non-vertebral fracture, PF pathologic fracture, Q quartile, RB radiation
to bone, SB surgery to bone, SCC spinal cord compression, SRE skeletal-related event, UK United Kingdom, VF vertebral fracture.
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patient visits per SRE (6.8 [SD 6.7] visits), with the number
of visits required for other SREs ranging from 1.8 (SD 3.6)
for surgery to bone to 4.1 (SD 6.3) for spinal cord com-
pression. In the UK, the mean number of outpatient visits
required per SRE (2.5 [SD 2.7]) was half that of the overall
mean. The low number of visits required for radiation to
bone (2.6 [SD 2.4]) was probably the greatest contributor
to this. In Italy, the mean number of visits required for
spinal cord compression was low (1.6 [SD 2.5]).
Procedures performed
Across all the countries, almost all SREs required a pro-
cedure (90.7–100% across the different SRE types),
with external-beam radiation the most common proced-
ure type (Figure 6).SREs required a mean of 7.1 (SD 7.1) procedures per
SRE overall (Figure 7). Radiation to bone and spinal cord
compression were associated with the highest number of
procedures (9.1 [SD 7.3] and 7.4 [SD 7.2], respectively),
with external-beam radiation the most common proced-
ure performed for both. Most procedures were per-
formed in an outpatient setting (5.4 [SD 6.7] procedures
per SRE); 1.5 (SD 4.1) procedures per SRE required an
overnight stay, with spinal cord compression most likely
to require this. Procedures requiring an emergency room
visit were rare (0.1 [SD 0.4] procedures per SRE).
Patients in the UK required the lowest number of pro-
cedures for radiation to bone, reflecting the pattern seen
for the number of outpatient visits required for this SRE.
Notably, the mean rates of external-beam radiation and
intensity-modulated radiation therapy (IMRT) per SRE













Facility n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Surgical unit/ward 50 15.3 (9.2) 18 20.2 (9.2) 1 24.0 (–) 17 19.9 (9.4) 0 – 2 17.0 (5.7) 30 12.2 (8.3)
Oncology unit/ward 39 14.4 (17.7) 7 9.6 (5.1) 3 8.0 (4.6) 4 10.8 (5.8) 20 11.0 (8.3) 8 28.6 (33.4) 4 11.3 (13.9)
Other 18 19.1 (23.5) 8 14.4 (8.8) 2 8.0 (5.7) 6 16.5 (8.9) 2 27.0 (0.0) 0 - 8 21.9 (34.9)
General unit/ward 10 19.9 (25.9) 5 29.0 (35.0) 1 87.0 (–) 4 14.5 (15.4) 4 9.0 (8.7) 1 18.0 (–) 0 –
Radiation unit/ward 8 20.8 (12.7) 2 24.5 (3.5) 2 24.5 (3.5) 0 – 4 18.8 (18.0) 2 21.0 (9.9) 0 –
Rehabilitation unit/ward 6 29.8 (10.8) 2 36.0 (18.4) 1 49.0 (–) 1 23.0 (–) 0 – 1 22.0 (–) 3 28.3 (7.1)
Gynecology unit/ward 1 33.0 (–) 0 – 0 – 0 – 0 – 1 33.0 (–) 0 –
Intensive care unit/ward 1 4.0 (–) 0 – 0 – 0 – 0 – 0 – 1 4.0 (–)
Nursing facility 1 26.0 (–) 1 26.0 (–) 0 – 1 26.0 (–) 0 – 0 – 0 –
Rehabilitation facility 1 5.0 (–) 0 – 0 – 0 – 0 – 0 – 1 5.0 (–)
aVertebral fracture and non-vertebral fracture are subsets of pathologic fracture.
n = Number of SREs with at least one inpatient stay within facility type and SRE type. (If an SRE required stays in more than one facility type, a stay was attributed
to each facility type for the appropriate duration. If an SRE had multiple inpatient stays within one facility type, the total duration of inpatient stays was counted).
SD-standard deviation, SRE-skeletal-related event.
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Germany recorded the highest number of procedures for
radiation to bone, which were mostly performed in an
outpatient setting. These were mainly external-beam ra-
diation (8.6 [SD 8.2] per SRE) and IMRT (4.0 [SD 7.6]
per SRE).
Emergency room and home health visits, and nursing
home/long-term care facility stays
Very few home health visits (one in every 100 SREs) and











































Figure 4 Proportion of SREs requiring an outpatient visit. VF and NVF
PF pathologic fracture, RB radiation to bone, SB surgery to bone, SCC spinareported, and only four patients required a stay in a
nursing home/long-term care facility.
Discussion
This is the first large, prospective study investigating
HRU associated with different types of SRE in patients
with breast cancer metastatic to bone in Europe. We
found that all SREs were associated with substantial HRU,
with lengthy hospitalizations frequently required. This is
also the first study in which HRU has been assigned to








are subsets of PF n = number of SREs. NVF non-vertebral fracture,













































Figure 5 Mean number of outpatient visits per SRE. Data are shown as mean (+standard deviation). Median (Q1, Q3) data are displayed
below the graph. VF and NVF are subsets of PF. n = number of SREs requiring an inpatient stay with at least one inpatient stay within each SRE
type. NVF non-vertebral fracture, PF pathologic fracture, Q quartile, RB radiation to bone, SB surgery to bone, SCC spinal cord compression, SRE
skeletal-related event, VF vertebral fracture.
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by investigators’ expert opinion to be a direct consequence
of the SRE, rather than owing to the underlying disease.
Patient characteristics at enrollment were broadly
similar across the different countries. However, patients
in the UK had a higher rate of SREs per patient-year
than those from the three other European countries
studied, which may reflect the longer median time from
the detection of bone metastases to enrollment in the
study in the UK (approximately double that seen for the
other countries). Despite this, the ECOG performance
status of patients in the UK showed a similar distribu-
tion to those from Germany and Italy, whereas Spain
had a higher proportion of patients with a poorer ECOG
performance status of 2.
In general, patterns of HRU were similar across the four
European countries studied. The overall patterns of HRU






































































Figure 6 Mean number of procedures performed per SRE by type. Me
1.0); all other procedure types: 0.0 (0.0, 0.0). Data are shown as mean (+stan
radiation therapy, MRI magnetic resonance imaging, Q quartile.studies by Gunther et al. in Austria, the Czech Republic,
Poland, Sweden, and Switzerland (Gunther et al. 2011), by
Felix et al. in Portugal (Felix et al. 2011), and by Svendsen
et al. in Denmark (Svendsen et al. 2013). All of these stud-
ies found SREs were associated with lengthy inpatient
stays, which were major contributors to the overall cost of
care.
Inpatient stays were particularly common with spinal
cord compression and surgery to bone. Although spinal
cord compression was rare, it required the longest hos-
pital stays. This is consistent with two separate eco-
nomic analyses illustrating the high cost of each spinal
cord compression event (Felix et al. 2011; Barlev et al.
2010). Notably, surgery to bone required shorter in-
patient stays than pathologic fracture, probably because
surgery facilitates faster stabilization of bone. Radiation
to bone is one of the most common SREs in patients































































dian (Q1, Q3) for external-beam radiation: 1.0 (0.0, 8.0); X-ray: 0.0 (0.0,







































Figure 7 Mean number of procedures per SRE. Data are shown as mean (+standard deviation). Median (Q1, Q3) data are displayed below
the graph. VF and NVF are subsets of PF. n = number of SREs. NVF non-vertebral fracture, PF pathologic fracture, Q quartile, RB radiation to bone,
SB surgery to bone, SCC spinal cord compression, VF vertebral fracture.
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associated with a considerable proportion of hospitaliza-
tions. This may have been owing to complications requir-
ing an inpatient stay or patients being required to travel
substantial distances for multifractionated radiotherapy.
Approximately three-quarters of SREs were associated
with outpatient visits, with a mean of five visits per SRE.
Therefore, outpatient visits may also impose a consider-
able burden on healthcare resources in Europe. In an
analysis of the economic burden of bone metastases in
the USA, outpatient visits were found to be the biggest
contributor to incremental costs associated with bone
metastases, accounting for 63–71% of the additional
costs compared with patients without bone metastases
(Schulman and Kohles 2007).
Radiation to bone was associated with the greatest
number of procedures per SRE, in addition to the high-
est number of outpatient visits. Our findings therefore
suggest that radiation to bone is a major contributor to
the increased burden that SREs place on healthcare sys-
tems, consistent with similar results in other studies
(Lage et al. 2008; Decroisette et al. 2011; Felix et al.
2011). The high numbers of outpatient visits and proce-
dures observed in our study probably reflect the use of
multiple fractions of radiotherapy. A study in patients
with breast or prostate cancer with bone metastases in
Portugal reported a mean of 8.4 sessions per treatment
for radiation to bone (Felix et al. 2011). In a retrospect-
ive study of palliative radiotherapy for bone metastases
in Spain, only 25% of cases received single-fraction
(800 cGy) treatment, with 59% receiving five- or ten-
fraction regimens (Expósito et al. 2012). The lower num-
ber of procedures and outpatient visits reported in
the UK for radiation to bone is probably owing to a pref-
erence for single-fraction radiotherapy over multiple-
fraction treatment. Surveys of radiotherapy for bone
metastases in the UK reported a mean of about threefractions per treatment, with approximately 60% of treat-
ments delivered as a single fraction (Williams et al.
2007; Royal College of Radiologists 2007). The length of
inpatient stay for radiation to bone was also much
shorter in the UK than elsewhere, which could again re-
flect the preference for single-fraction over multiple-
fraction radiotherapy.
Our study had some limitations. As discussed in
Hoefeler et al., the duration of follow-up for this study
was shorter than planned (6.9–10.9 months) owing to
slow recruitment (possibly because the trial was non-
interventional) and early withdrawal from the study as a
result of patient death (Hechmati et al. 2011). The sam-
ple sizes for surgery to bone and spinal cord compres-
sion were limited and may not have been sufficient to
provide a generalizable HRU estimation. Similarly, the
applicability of estimations of the duration of inpatient
stays may have been limited by the small sample sizes.
Other limitations to the study included some data being
inaccessible to investigators at all study sites. For ex-
ample, information about home health visits or nursing
home stays was not always relayed back to the main hos-
pital, making it difficult to capture resource use associ-
ated with these events. It should also be noted that the
incidence of SREs reported here is not representative of
the real-world distribution of SRE types, because they
are impacted by the index SRE recruitment cells and the
inclusion criteria stating patients must have an ECOG
performance status of 2 or less and a life expectancy of
at least 6 months. Furthermore, pain was not defined
as an SRE, although this common complication from
poorly treated bone metastases could have led to sub-
stantial HRU and lengthy inpatient stays. These limita-
tions would be expected to result in an underestimation
of the overall HRU associated with SREs, and therefore
the true burden of SREs may be even greater than sug-
gested by these results.
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with bone metastases secondary to breast cancer would
substantially reduce HRU. Bisphosphonates, such as zo-
ledronic acid, have been widely used to reduce the oc-
currence of SREs. Denosumab, a monoclonal antibody
to RANKL, has recently been approved for the preven-
tion of SREs in patients with bone metastases from solid
tumors (European Medicines Agency 2012), and has
been shown to be superior to zoledronic acid at reducing
the incidence of SREs (Fizazi et al. 2011; Henry et al.
2011; Stopeck et al. 2010).
In conclusion, all types of SRE arising from bone me-
tastases in patients with breast cancer are associated
with considerable HRU. Therefore, treatments that delay
or prevent SREs may reduce the burden imposed on
healthcare systems across Europe.
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